natgillin/translations-raw huggingface dataset:
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER injektionsvæske, suspension Pandemisk influenzavaccine (H5N1) (hel virion, inaktiveret, fremstillet i cellekultur) i.m.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER suspension for injection Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) I.M.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER må ikke gives samtidig med andre vacciner.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER should not be given at the same time as other vaccines.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER må under ingen omstændigheder indgives intravaskulært.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER should under no circumstances be administered intravascularly.
Pandemisk influenza er en type influenza, som opstår i tidsintervaller, der varierer fra under 10 år til årtier.
Pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades.
Pandemisk influenza-vaccine (H1N1)v (split virion, inaktiveret, adjuveret)
Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
Pandemisk influenzavaccine (H5N1) (levende svækket, nasal)
Pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Pandemisk influenzavaccine (hele virion, inaktiveret, adjuveret)
Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Pandemisk influenzavaccine (hele virion, inaktiveret, adjuveret) Intramuskulært
Pandemic influenza vaccine (whole virion, inactivated, adjuvanted) I.M.
Pandemisk influenzavaccine (overfladeantigen, inaktiveret, adjuveret)
Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Pandemisk influenzavaccine (overfladeantigener, inaktiveret, adjuveret)
Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Pandemisk influenzavaccine bør anvendes i overensstemmelse med officielle retningslinjer (se afsnit 4.2 og 5.1).
Pandemic influenza vaccine should be used in accordance with official guidance. (see sections 4.2 and 5.1)
Pandemisk influenzavaccine H5N1 MedImmune administreres som en delt dosis i begge næsebor som beskrevet nedenfor. (Se også Sådan skal Pandemisk influenzavaccine H5N1 MedImmune gives, i punkt 3).
Pandemic influenza vaccine H5N1 MedImmune is administered as a divided dose in both nostrils as described below. (See also How Pandemic influenza vaccine H5N1 MedImmune is given, in section 3).
Pandemisk influenzavaccine H5N1 MedImmune administreres som en delt dosis i begge næsebor.
Pandemic influenza vaccine H5N1 MedImmune is administered as a divided dose in both nostrils.
Pandemisk influenzavaccine H5N1 MedImmune er en beredskabsvaccine til håndtering af en pandemi.
Pandemic influenza vaccine H5N1 MedImmune is a pandemic preparedness vaccine.
Pandemisk influenzavaccine H5N1 MedImmune er en vaccine til forebyggelse af influenza under en officielt erklæret pandemi (verdensomspændende epidemi).
Pandemic influenza vaccine H5N1 MedImmune is a vaccine to prevent influenza (flu) in an officially declared pandemic.
Pandemisk influenzavaccine H5N1 MedImmune er en vaccine, der er udviklet til at beskytte børn og unge i alderen 12 måneder til 18 år mod influenza under en influenzapandemi.
Pandemic influenza vaccine H5N1 MedImmune is a vaccine developed to protect children aged between 12 months and 18 years against influenza (flu) during a flu pandemic.
Pandemisk influenzavaccine H5N1 MedImmune er kun til nasal anvendelse.
Pandemic influenza vaccine H5N1 MedImmune is for nasal use only.
Pandemisk influenzavaccine H5N1 MedImmune frarådes til ammende kvinder.
Pandemic influenza vaccine H5N1 MedImmune is not recommended for breast-feeding women.
Pandemisk influenzavaccine H5N1 MedImmune fås som næsespray.
Pandemic influenza vaccine H5N1 MedImmune is available as a nasal spray.
Pandemisk influenzavaccine H5N1 MedImmune gives som spray i begge næsebor.
Pandemic influenza vaccine H5N1 MedImmune will be given as a spray in each nostril.
Pandemisk influenzavaccine H5N1 MedImmune har fået en "betinget godkendelse".
Pandemic influenza vaccine H5N1 MedImmune has been given ‘conditional approval’.
Pandemisk influenzavaccine H5N1 MedImmune indeholder en levende, svækket stamme af typen influenza A-virus A/Vietnam/1203/2004 (H5N1).
Pandemic influenza vaccine H5N1 MedImmune contains live, attenuated (weakened) influenza A virus A/Vietnam/1203/2004 (H5N1) strain.
Pandemisk influenzavaccine H5N1 MedImmune leveres som en 0,2 ml suspension i en nasalapplikator (type 1-glas) til engangsbrug, med spids (polypropylen med overførselsventil af polyethylen), beskyttelseshætte til spidsen (syntetisk gummi), stempelstang, stempel (butylgummi) og en klemme til dosisdeling.
Pandemic influenza vaccine H5N1 MedImmune is supplied as a 0.2 ml suspension in a single-use nasal applicator (Type 1 glass), with nozzle (polypropylene with polyethylene transfer valve), nozzle tip-protector cap (synthetic rubber), plunger rod, plunger-stopper (butyl rubber), and a dose-divider clip.
Pandemisk influenzavaccine H5N1 MedImmune må generelt ikke gives til børn, der har haft en alvorlig allergisk reaktion på et af stofferne i vaccinen, herunder gelatine og gentamicin, eller til børn, der har haft en alvorlig allergisk reaktion på æg eller æggeproteiner, f.eks. ovalbumin.
Pandemic influenza vaccine H5N1 MedImmune must not generally be given to children who have had a severe allergic reaction to any of the substances in the vaccine including gelatin and gentamicin or to children who have had a severe allergic reaction to eggs or egg proteins, such as ovalbumin.
Pandemisk influenzavaccine H5N1 MedImmune må ikke anvendes, hvis udløbsdatoen er overskredet eller hvis spraydelen virker beskadiget, for eksempel hvis stemplet er løst eller ikke isat spraydelen eller hvis der er tegn på lækage.
Do not use Pandemic influenza vaccine H5N1 MedImmune if the expiry date has passed or the sprayer appears damaged, for example, if the plunger is loose or displaced from the sprayer or if there are any signs of leakage.
Pandemisk influenzavaccine H5N1 MedImmune må ikke anvendes, hvis udløbsdatoen er overskredet, eller hvis spraydelen virker beskadiget, for eksempel hvis stemplet er løst eller ikke sidder i spraydelen, eller hvis der er tegn på lækage.
Do not use Pandemic influenza vaccine H5N1 MedImmune if the expiry date has passed or if the sprayer appears damaged, for example, if the plunger is loose or displaced from the sprayer or if there are any signs of leakage.
Pandemisk influenzavaccine H5N1 MedImmune må ikke gives som indsprøjtning.
Pandemic influenza vaccine H5N1 MedImmune must not be injected.
Pandemisk influenzavaccine H5N1 MedImmune må ikke injiceres.
Do not inject Pandemic influenza vaccine H5N1 MedImmune.
Pandemisk influenzavaccine H5N1 MedImmune må kun anvendes som næsespray.
Pandemic influenza vaccine H5N1 MedImmune must only be used as a nasal spray.
Pandemisk influenzavaccine H5N1 MedImmune næsespray, suspension Pandemisk influenzavaccine (H5N1) (levende svækket, nasal)
Pandemic influenza vaccine H5N1 MedImmune nasal spray, suspension Pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Pandemisk influenzavaccine H5N1 MedImmune næsespray, suspension Pandemisk influenzavaccine (levende svækket, nasal)
Pandemic influenza vaccine H5N1 MedImmune nasal spray, suspension Pandemic influenza vaccine (live attenuated, nasal)
Pandemisk influenzavaccine H5N1 MedImmune Pandemisk influenzavaccine
Pandemic influenza vaccine H5N1 MedImmune Pandemic influenza vaccine
Pandemisk influenzavaccine H5N1 MedImmune pandemisk influenzavaccine (levende svækket, nasal)
Pandemic influenza vaccine H5N1 MedImmune pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Pandemisk influenzavaccine H5N1 MedImmune påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Pandemic influenza vaccine H5N1 MedImmune has no or negligible influence on the ability to drive and use machines.
Pandemisk influenzavaccine H5N1 MedImmune påvirker ikke eller kun i ubetydelig grad evnen til at køre motorkøretøj og bruge maskiner.
Pandemic influenza vaccine H5N1 MedImmune has no or negligible influence on the ability to drive and use machines.
Pandemisk influenzavaccine H5N1 MedImmune skal anvendes i overensstemmelse med officielle retningslinjer.
Pandemic influenza vaccine H5N1 MedImmune should be used in accordance with official guidance.
Pandemisk influenzavaccine H5N1 MedImmune svarer til Fluenz Tetra (en influenzavaccine til brug i næsen, der indeholder fire virus-stammer) bortset fra, at Pandemisk influenzavaccine H5N1 MedImmune giver beskyttelse mod en enkelt influenzastamme i en officielt erklæret pandemi.
Pandemic influenza vaccine H5N1 MedImmune is similar to Fluenz Tetra (a nasal influenza vaccine containing four strains), except Pandemic influenza vaccine H5N1 MedImmune provides protection against a single influenza strain in an officially declared pandemic.
Pandemisk influenzavaccine H5N1 MedImmune vil blive indgivet under overvågning af en læge eller sygeplejerske.
Pandemic influenza vaccine H5N1 MedImmune will be administered under the supervision of a doctor, nurse or pharmacist.
Pandemisk influenzavaccine H5N1 MedImmune, næsespray, suspension
Pandemic influenza vaccine H5N1 MedImmune, nasal spray suspension
Pandemiske og præpandemiske vacciner indeholder influenza-antigener, som er anderledes end antigenerne i de aktuelt cirkulerende influenzavira.
Pandemic and Prepandemic vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses.
Pandemrix blev oprindeligt godkendt under ”særlige omstændigheder”, da der af videnskabelige årsager kun forelå begrænsede oplysninger på godkendelsestidspunktet.
Pandemrix was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Pandemrix blev oprindeligt udviklet som en pandemisk vaccine til brug under influenza A (H1N1)- pandemien, som blev erklæret i juni 2009.
Pandemrix was originally developed as a pandemic vaccine, and was used during the influenza A (H1N1) pandemic declared in June 2009.
Pandemrix indeholder små mængder af
Pandemrix contains small amounts of haemagglutinins (proteins
Pandemrix suspension og emulsion til injektionsvæske, emulsion
Pandemrix suspension and emulsion for emulsion for injection
Pandemrix suspension og emulsion til injektionsvæske, emulsion.
Pandemrix suspension and emulsion for emulsion for injection.
Panelet af inducerede cytokiner varierer med cellens vævsoprindelse.
The panel of induced cytokines varies with the cell’s tissue origin.
Panepistimiopolis Zografou 15771 Athens Attiki GRÆKENLAND
Panepistimiopolis Zografou 15771 Athens Attiki GREECE
Panikanfald
Panic attacks
Panikanfald, vanskelighed ved at tænke, rastløshed, humørsvingninger, depression, angst, hallucinationer, ændringer i seksuel aktivitet
Feeling of panic, difficulty thinking, restlessness, mood swings, depression, anxiety, hallucinations, changes in sex drive
Panikreaktion
Panic reaction
Panikreaktioner, depression, følelsesmæssig ustabilitet, tilstand af ligegyldighed med følelsesmæssig tomhed, emotionelt og mentalt ubehag, humørsvingninger
panic reaction, depression, affect lability, state of indifference with lack of emotion, feelings of emotional and mental discomfort, altered mood
Paniksymptomer Vrede Dysphoria Følelses- forstyrrelser Selvmordstanker Aggressivitet Aggressiv adfærd
Panic symptoms Anger Dysphoria Emotional disorder Suicidal ideation Aggressiveness Aggressive behaviour
Panitumumab er designet, så det binder sig til EGFR, der kan findes på overfladen af bestemte celler, herunder celler i visse tumorer.
Panitumumab has been designed to attach to EGFR, which can be found on the surface of certain cells, including cells in some tumours.
Panitumumab synes ikke at have nogen virkning på tumorceller, der indeholder muterede RAS-gener.
Panitumumab does not seem to work in tumour cells that contain mutated RAS genes.
Pankre- atitis, Stoma- titis
Carpal tunnel
Pankreatit
153 (12.3)
Pankreatit
pancreatitis
Pankreatit is11
Pancreatitis11
Pankreatit,
Pancreatitis.
Pankreatit.
pancreatitis
Pankreatit1, opkastning, gastroøsofageal reflukssygdom, gastroenterit og colitis, mavesmerter øvre og nedre), abdominal distension, dyspepsi, hæmorider flatulens
Pancreatitis1, vomiting, gastrooesophageal reflux disease, gastroenteritis and colitis, abdominal pain (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence
Pankreatitis
Mouth ulceration Pancreatitis
pankreatitis (autoimmun pankreatitis og akut pankreatitis)
pancreatitis (autoimmune pancreatitis and pancreatitis acute)
pankreatitis (betændelse i bugspytkirtlen );
pancreatitis (inflammation of the pancreas);
pankreatitis (betændelse i bugspytkirtlen), opkastning
pancreatitis (inflammation of the pancreas), vomiting
pankreatitis (inklusive akut pankreatitis), øvre gastrointestinalt ulcus, esophagitis, ascites*, analfissur, dysfagi, gastroøsofageal reflukssygdom
pancreatitis (including acute pancreatitis), upper gastrointestinal ulcer, oesophagitis, ascites*, anal fissure, dysphagia, gastroesophageal reflux disease
Pankreatitis Analfistler
Pancreatitis
Pankreatitis blev rapporteret hos < 1% af patienterne i studier med kombinationsbehandling med Zerit.
Pancreatitis was reported in < 1% of patients in combination therapy studies with Zerit.
Pankreatitis blev rapporteret hyppigere hos patienter randomiseret til linagliptin (5 tilfælde hos 4.302 linagliptin-behandlede patienter mod 1 tilfælde hos 2.364 placebo-behandlede).
Pancreatitis was reported more often in patients randomized to linagliptin (5 events in 4,302 patients receiving linagliptin versus 1 event in 2,364 patients receiving placebo).
Pankreatitis Dysfagi Diarré
Pancreatitis Dysphagia Diarrhoea
Pankreatitis er også blevet rapporteret post-marketing.
Pancreatitis was also reported post­marketing.
Pankreatitis er set ikke-almindelig (<1%) hos patienter, der får SUTENT for GIST eller mRCC.
Pancreatitis has been observed uncommonly (<1%) in patients receiving sunitinib for GIST or MRCC.
pankreatitis i forbindelse
pancreatitis in the
Pankreatitis ved ikke-foreskrevet anvendelse til behandling af patienter med inflammatorisk tarmsygdom
Pancreatitis in off-label treatment of patients with inflammatory bowel disease
pankreatitis, dysfagi, ubehag fra abdomen og maven, diarré
pancreatitis, dysphagia, abdominal discomfort, stomach discomfort, diarrhoea
pankreatitis, gastritis
pancreatitis, gastritis
pankreatitis, gastritis, aftøs stomatitis
pancreatitis, gastritis, stomatitis aphthous
pankreatitis, gastritis, gastroøsofageal
pancreatitis, gastritis, gastrooesophageal reflux
Pankreatitis, gastrointestinal perforation (herunder divertikulær og intestinal perforation samt tyktarmsperforation)^
Pancreatitis, Gastrointestinal perforation (including diverticular, intestinal and large intestine perforations) ^
Pankreatitis, iskæmisk colitis, opkastning
Pancreatitis; ischemic colitis; vomiting
pankreatitis, peritonitis, øget blodamylase, paralytisk ileus, gastroøsofageal reflukssygdom, nedsat ventrikel- tømning
chronic pancreatitis, peritonitis, blood amylase increased, ileus paralytic, gastrooeso- phageal reflux disease, impaired gastric emptying
Pankreatitis, stomatitis, ascites
Osteonecrosis
pankreatitis, ulcus pepticum, rektalblødning, gastritis
pancreatitis, peptic ulcer, rectal haemorrhage, gastritis
Pankreatitis.
Pancreatitis.
Pankreatitis11
aminotransferases
Pankreatitis11
distension9
Pankreatitis11
Pancreatitis
Pankreatitis: Kliniske undersøgelser har meldt om akut pankreatitis i forbindelse med forhøjede serumtriglycerider.
Pancreatitis: acute pancreatitis associated with elevations of fasting serum triglycerides has been reported in clinical studies.
Pankreatitisam, gastritisam, gingival hyperplasiam
Pancreatitisam, gastritisam, gingival hyperplasiaam
Pankreatitisc,
pancreatitisc, intestinal
pankreatitisi
pancreatitisi
Pannikulit, purpura, hudinduration, Stevens-Johnsons syndrom, pruritus
Panniculitis, Purpura, Skin induration, Stevens-Johnson syndrome, Pruritus
Panretin (N=134) N %4
Vehicle (N=134)
Panretin 0,1 % gel
Panretin 0.1 % gel
Panretin 0,1 % gel alitretinoin
Panretin 0.1 % gel alitretinoin
Panretin 0,1% gel alitretinoin
Panretin 0.1% gel Alitretinoin
Panretin anvendes hos patienter med AIDS-relateret Kaposis sarkom (KS) og er til behandling af de KS-læsioner:
Panretin is used in patients with AIDS-related Kaposi’s sarcoma (KS) and is for the treatment of the KS lesions:
Panretin er en klar, gul gel.
Panretin is a clear yellow gel.
Panretin er kontraindiceret (se afsnit 4.3) ved graviditet, da alitretinoin kan forårsage fosterskade, når det indgives systemisk til en gravid kvinde.
Panretin is contraindicated (see section 4.3) in pregnancy, as alitretinoin may cause foetal harm when administered systemically to a pregnant woman.
Panretin gel 0,1 %
Panretin gel 0.1
Panretin gel er indiceret til lokal behandling af kutane læsioner hos patienter med AIDS-relateret Kaposis sarkom (KS), når:
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma (KS) when:
Panretin gel er til kutan anvendelse, det er usandsynligt, at det skulle have nogen effekt på evnen til at føre motorkøretøj eller betjene maskiner.
Panretin gel is for cutaneous use and is unlikely to have an effect on one’s ability to drive or operate machines.
Panretin indeholder alkohol.
Panretin contains alcohol.
Panretin tihører en gruppe lægemidler, der er beslægtet med vitamin A og kendt som retinoider.
Panretin belongs to a group of medicines that are related to vitamin A and known as retinoids
Panretin udseende og pakningstørrelse
What Panretin looks like and contents of the pack
PANRETIN VIRKNING OG HVAD DE/DU SKAL BRUGE DET TIL
WHAT PANRETIN IS AND WHAT IT IS USED FOR
PANTECTA Control indeholder det aktive stof pantoprazol, som blokerer den ”pumpe”, der producerer mavesyre.
PANTECTA Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
PANTECTA Control kan reducere absorptionen af aktive stoffer, hvis biotilgængelighed er pH- afhængig (fx. ketoconazol).
PANTECTA Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Pantecta Control svarer til et referencelægemiddel ved navn Pantecta, som allerede er godkendt i Den Europæiske Union (EU).
Pantecta Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantecta.
Pantienter med nedsat nyrefunktion
Patients with impaired kidney function
PANTOLOC Control 20 mg enterotabletter
PANTOLOC Control 20 mg gastro-resistant tablets
PANTOLOC Control bør ikke anvendes under amning.
Pantoprazole should not be used during breast-feeding.
PANTOLOC Control indeholder det aktive stof pantoprazol, som blokerer den ”pumpe”, der producerer mavesyre.
PANTOLOC Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
PANTOLOC Control kan reducere absorptionen af aktive stoffer, hvis biotilgængelighed er pH- afhængig (fx. ketoconazol).
PANTOLOC Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Pantoloc Control svarer til et referencelægemiddel ved navn Pantoloc, som allerede er godkendt i Den Europæiske Union (EU).
Pantoloc Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantoloc.
Pantoprazol
Terfenadine
Pantoprazol bliver næsten udelukkende metaboliseret i leveren.
Pantoprazole is almost exclusively metabolized in the liver.
Pantoprazol har konstant vist sig at være bedre end placebo og H2-receptor-antagonister og ikke mindre effektive end andre PPI’er.
Pantoprazole was consistently shown to be superior to placebo and H2RA and non-inferior to other PPIs.
Pantoprazol og andre protonpumpehæmmere (PPI) blev givet sammen med Pradaxa i kliniske studier, og samtidig PPI behandling syntes ikke at reducere virkningen af Pradaxa.
Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa.
Pantoprazol omdannes til dets aktive form, en cyklisk sulfonamid, i det sure miljø i parietalcellerne, hvor det hæmmer H+/K+-ATPase enzymet, dvs. det sidste stadie i produktionen af saltsyre i maven.
Pantoprazole is converted to its active form, a cyclic sulphenamide, in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach.
Pantoprazol: Co-administration af pantoprazol (80 mg 1 gang dagligt) påvirkede ikke de farmakokinetiske egenskaber af cinacalcet.
Pantoprazole: Co-administration of pantoprazole (80 mg, once daily) did not alter the pharmacokinetics of cinacalcet.
PANTOZOL Control bør ikke anvendes under amning.
Pantoprazole should not be used during breast-feeding.
PANTOZOL Control indeholder det aktive stof pantoprazol, som blokerer den ”pumpe”, der producerer mavesyre.
PANTOZOL Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
PANTOZOL Control kan reducere absorptionen af aktive stoffer, hvis biotilgængelighed er pH- afhængig (fx. ketoconazol).
PANTOZOL Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Pantozol Control svarer til et referencelægemiddel ved navn Pantozol, som allerede er godkendt i Den Europæiske Union (EU).
Pantozol Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantozol.
Pap til Al/Al blister
Carton for Al/Al blister
Pap til Al/PVC/PVDC blister
Carton for Al/PVC/PVDC blister
Pap til HDPE tabletbeholder
Carton for HDPE tablet container
Pap-emballage 10, 32, 100, 2 x 100 og 200 ml flaske
Carton box 10, 32, 100, 2 x 100 ml and 200 ml bottle
Papaverin (bruges til at forbedre blodgennemstrømningen rundt i kroppen)
Papaverine (used to improve blood flow around the body)
Papeller (små forhøjelser i huden)
Papules (small skin elevations)
Papeller på påføringsstedet
Application site scabbing
Papil-ødem
Papilloedema
Papillom blev anset for at være behandlingsrelateret men ikke dosisrelateret.
Papilloma was considered treatment related, but not dose related.
Papillomc
Papillomac
Papillomer i huden
skin papilloma
Papillær thyroideacancer: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Papillary thyroid cancer: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
papilødem, tab af synsskarphed eller synsfelt, slørede
papilloedema, loss of visual acuity or visual field, cotton
Papir-
Pen cap
Papir- forsegling
Paper tab
Papirflig
Paper Tab
Papkarton indeholdende 1 hætteglas lyofilisat og 1 hætteglas solvens.
Cardboard box containing 1 vial of lyophilisate and 1 vial of solvent.
Papkarton indeholdende 1, 2, 4 eller 10 alu/alu blisterkort.
Cardboard box containing 1, 2, 4 or 10 Alu/Alu blisters.
Papkarton indeholdende 1, 2, 5 eller 10 alu/alu blisterkort.
Cardboard box containing 1, 2, 5 or 10 Alu/Alu blisters.
Papkarton indeholdende 10 hætteglas lyofilisat og 10 hætteglas solvens.
Cardboard box containing 10 vials of lyophilisate and 10 vials of solvent.
Papkarton indeholdende 5 hætteglas lyofilisat og 5 hætteglas solvens.
Cardboard box containing 5 vials of lyophilisate and 5 vials of solvent.
Papkarton indeholdende et farveløst hætteglas à 10 ml eller 20 ml, lukket med gummiprop og forseglet med aluminiumshætte.
Cardboard box containing one colourless glass injection vial of 10 ml or 20 ml, closed with a rubber stopper and sealed with an aluminium cap.
Papkarton med et hætteglas af polyethylenterephthalat (PET) indeholdende 250 ml (1000 doser) eller 500 ml (2000 doser), lukket med en halogenobutyl gummiprop og forseglet med en kodet aluminiumshætte.
Carton box with one Polyethylene Terephthalate (PET) vial of 250 ml (1000 doses) or 500 ml (2000 doses), closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.